Paclitaxel-coated balloon treatment was associated with favorable outcomes, including LLE and a reduction in maxLCBI4mm, irrespective of lipid burden. However, the mechanisms underlying LLE may differ between lipid-rich and non-lipid-rich lesions, suggesting potential heterogeneity in biological responses to DCB therapy.
Matsuhiro et al. (Tue,) studied this question.